New research presented identifies interferon-induced transmembrane protein 3 (IFITM3) as a critical regulator of immunotherapy sensitivity in small cell lung cancer (SCLC), offering a promising new avenue for overcoming resistance to PD-1/PD-L1 checkpoint blockade.
from News Medical Medical Research News Feed https://ift.tt/OEW57Xv
0 Comments